$AZN making moves in rare disease space—reportedly offered ~$10B ($124/share) for $RYTM last month per WSJ.
Big pharma's rare disease shopping spree continues. AstraZeneca already has a decent rare disease portfolio, but clearly sees something compelling in Rhythm's pipeline.
For context: Rhythm specializes in genetic obesity disorders. Their lead drug Imcivree targets rare forms of obesity caused by specific genetic mutations—think MC4R pathway deficiencies.
The $124 offer represents a meaningful premium. Classic bolt-on M&A playbook: established pharma buys specialized biotech with proven mechanism, expands treatment portfolio, leverages distribution.
Rare disease = smaller patient populations but premium pricing and longer patent runway. Math works when you have AZN's global reach.
Worth watching if this closes or if competing bids emerge.
Big pharma's rare disease shopping spree continues. AstraZeneca already has a decent rare disease portfolio, but clearly sees something compelling in Rhythm's pipeline.
For context: Rhythm specializes in genetic obesity disorders. Their lead drug Imcivree targets rare forms of obesity caused by specific genetic mutations—think MC4R pathway deficiencies.
The $124 offer represents a meaningful premium. Classic bolt-on M&A playbook: established pharma buys specialized biotech with proven mechanism, expands treatment portfolio, leverages distribution.
Rare disease = smaller patient populations but premium pricing and longer patent runway. Math works when you have AZN's global reach.
Worth watching if this closes or if competing bids emerge.
